Dashboard
Manage Tickers

INZYInozyme Pharma, Inc.

Nasdaq inozyme.com


$ 4.50 $ -0.07 (-1.53 %)    

Friday, 19-Apr-2024 15:59:57 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 414.59 $ -8.76 (-2.07 %)
DIA $ 379.83 $ 1.96 (0.52 %)
SPY $ 494.96 $ -4.36 (-0.87 %)
TLT $ 89.15 $ 0.32 (0.36 %)
GLD $ 221.02 $ 0.69 (0.31 %)
$ 4.51
$ 4.59
$ 4.50 x 400
$ 4.51 x 400
$ 4.38 - $ 4.62
$ 2.69 - $ 7.80
591,071
na
233.79M
$ 0.95
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-12-2024 12-31-2023 10-K
2 11-07-2023 09-30-2023 10-Q
3 08-08-2023 06-30-2023 10-Q
4 05-09-2023 03-31-2023 10-Q
5 03-22-2023 12-31-2022 10-K
6 11-10-2022 09-30-2022 10-Q
7 08-15-2022 06-30-2022 10-Q
8 05-10-2022 03-31-2022 10-Q
9 03-15-2022 12-31-2021 10-K
10 11-09-2021 09-30-2021 10-Q
11 08-11-2021 06-30-2021 10-Q
12 05-12-2021 03-31-2021 10-Q
13 03-25-2021 12-31-2020 10-K
14 11-12-2020 09-30-2020 10-Q
15 09-03-2020 06-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

needham-reiterates-buy-on-inozyme-pharma-maintains-23-price-target
Needham Reiterates Buy on Inozyme Pharma, ...
04/10/2024 10:43:01

Needham analyst Joseph Stringer reiterates Inozyme Pharma (NASDAQ:INZY) with a Buy and maintains $23 price target.

why-tilray-brands-shares-are-trading-lower-by-around-22-here-are-other-stocks-moving-in-tuesdays-mid-day-session
Why Tilray Brands Shares Are Trading Lower...
04/09/2024 17:12:29

Shares of Tilray Brands, Inc. (NASDAQ: TLRY) fell sharply during Tuesday’s session after the company missed third-quarter esti...

b-of-a-securities-maintains-buy-on-inozyme-pharma-lowers-price-target-to-14
B of A Securities Maintains Buy on Inozyme...
04/09/2024 16:38:02

B of A Securities analyst Tazeen Ahmad maintains Inozyme Pharma (NASDAQ:INZY) with a Buy and lowers the price target from $1...

needham-reiterates-buy-on-inozyme-pharma-maintains-23-price-target
Needham Reiterates Buy on Inozyme Pharma, ...
04/09/2024 11:56:05

Needham analyst Joseph Stringer reiterates Inozyme Pharma (NASDAQ:INZY) with a Buy and maintains $23 price target.

inozyme-pharma-announces-topline-data-from-ongoing-phase-12-trials-of-inz-701-in-adults-with-abcc6-deficiency-pxe-and-enpp1-deficiency
Inozyme Pharma Announces Topline Data from...
04/08/2024 10:31:36

 Inozyme Pharma, Inc. (NASDAQ:INZY) ("the Company" or "Inozyme"), a clinical-stage rare disease biopharmaceutic...

top-5-health-care-stocks-that-may-plunge-in-march
Top 5 Health Care Stocks That May Plunge I...
03/28/2024 12:30:01

As of March 28, 2024, five stocks in the health care sector could be flashing a real warning to investors who value momentum as...

inozyme-pharma-to-report-topline-data-from-ongoing-phase-12-trials-of-inz-701-in-adults-with-abcc6-deficiency-and-enpp1-deficiency-on-april-8-2024
Inozyme Pharma To Report Topline Data From...
03/26/2024 12:31:36

- Company to host conference call and webcast featuring key opinion leaders on Monday, April 8, 2024 at 8:00 a.m. ET -

hc-wainwright--co-maintains-buy-on-inozyme-pharma-maintains-16-price-target
HC Wainwright & Co. Maintains Buy on Inozy...
03/13/2024 13:29:55

HC Wainwright & Co. analyst Edward White maintains Inozyme Pharma (NASDAQ:INZY) with a Buy and maintains $16 price target.

inozyme-pharma-q4-earnings-insights
Inozyme Pharma: Q4 Earnings Insights
03/12/2024 21:50:18

needham-reiterates-buy-on-inozyme-pharma-maintains-23-price-target
Needham Reiterates Buy on Inozyme Pharma, ...
03/12/2024 16:36:27

Needham analyst Joseph Stringer reiterates Inozyme Pharma (NASDAQ:INZY) with a Buy and maintains $23 price target.

inozyme-fy23-eps-137-vs-178-yoy-cash-cash-equivalents-and-short-term-investments-were-1886m-as-of-december-31-2023
Inozyme FY23 EPS $(1.37) Vs $(1.78) YoY; C...
03/12/2024 13:00:07

Financial Results for the Year Ended December 31, 2023 Cash Position and Financial Guidance – Cash, cash equivalents, and short...

wedbush-reiterates-outperform-on-inozyme-pharma-maintains-15-price-target
Wedbush Reiterates Outperform on Inozyme P...
01/30/2024 15:52:19

Wedbush analyst David Nierengarten reiterates Inozyme Pharma (NASDAQ:INZY) with a Outperform and maintains $15 price target.

needham-reiterates-buy-on-inozyme-pharma-maintains-23-price-target
Needham Reiterates Buy on Inozyme Pharma, ...
11/08/2023 09:52:32

Needham analyst Joseph Stringer reiterates Inozyme Pharma (NASDAQ:INZY) with a Buy and maintains $23 price target.

inozyme-pharma-q3-eps-029-beats-032-estimate
Inozyme Pharma Q3 EPS $(0.29) Beats $(0.32...
11/07/2023 13:33:03

Inozyme Pharma (NASDAQ:INZY) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0.32...

inozyme-pharma-highlights-inclusion-of-generalized-arterial-calcification-of-infancy-in-genomics-englands-generation-study-of-rare-conditions
Inozyme Pharma Highlights Inclusion Of Gen...
10/10/2023 12:35:28

Inozyme Pharma, Inc. (NASDAQ:INZY) ("Inozyme" or the "Company"), a clinical-stage rare disease biopharmaceutica...

6-analysts-have-this-to-say-about-inozyme-pharma
6 Analysts Have This to Say About Inozyme ...
09/27/2023 18:00:32

needham-reiterates-buy-on-inozyme-pharma-maintains-23-price-target
Needham Reiterates Buy on Inozyme Pharma, ...
09/27/2023 10:31:04

Needham analyst Joseph Stringer reiterates Inozyme Pharma (NASDAQ:INZY) with a Buy and maintains $23 price target.

inozyme-pharma-posts-encouraging-data-from-rare-calcification-disorders
Inozyme Pharma Posts Encouraging Data From...
09/26/2023 18:43:58

Inozyme Pharma Inc (NASDAQ: INZY) announced interim safety, pharmacokinetic (PK), pharmacodynamic (PD), and exploratory efficac...

inozyme-pharma-announces-interim-data-from-ongoing-phase-12-trials-of-inz-701-in-adults-with-enpp1-deficiency-and-abcc6-deficiency-pxe
Inozyme Pharma Announces Interim Data from...
09/26/2023 11:37:56

 Inozyme Pharma, Inc. (NASDAQ:INZY) ("Inozyme" or the "Company"), a clinical-stage rare disease biopharmaceutic...

12-health-care-stocks-moving-in-mondays-after-market-session
12 Health Care Stocks Moving In Monday's A...
09/25/2023 21:31:33

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

04/22/2024 Dick's Sporting Goods, Inc. (DKS)
04/22/2024 Innodata Inc. (INOD)
04/22/2024 Fox Factory Holding Corp. (FOXF)
04/23/2024 Lantronix, Inc. (LTRX)

NEW CASE INVESTIGATION

AnaptysBio Inc (ANAB)